The benefits of early diagnosis of CTX
Learn how a vigilant pediatric ophthalmologist identified a case of CTX in a
For US HCPs Only
A 55-year-old adult was admitted to the hospital for investigations relating to a slowly progressive paraparesia and joint deformities.1
Patient had difficulty in standing and walking since infancy and had also suffered from bilateral juvenile cataracts. Patient was unable to complete their education because of intellectual disability. Three siblings had died in childhood, one from an undiagnosed neurological disorder. It was unknown whether patient's parents were related.
Physical examination revealed tendon xanthomas—firm, round, noninflammatory, subcutaneous tumors measuring 6 cm in diameter over the knees and elbows, which adhered to tendons. This patient also had yellowish papules of 2 to 3 mm in diameter in the superior eyelid compatible with xanthelasmas.1
Neurological findings included: mental retardation, spastic-ataxic gait, bilateral Babinski sign, symmetric amiotrophia on inferior and superior extremities, and hyperactive deep tendon reflexes with associated left Achilles clonus. Ligamentous hyperlaxity was also observed. The electroencephalogram showed a mild disorganization of the basic activity of theta waves.
Standard laboratory test values were normal. A biopsy from the left knee showed an infiltrate of foam cells surrounded by fibrous tracts. Inflammatory cells such as lymphocytes, histiocytes, and neutrophils were observed around the foam cells in some areas and a cholesterol cleft was found.
Magnetic resonance imaging revealed cerebral and cerebellar atrophy and hyperintense signals in the mesencephalic peduncles, protuberance, and cerebellar hemispheres.
Because of these symptoms CTX was suspected and later confirmed by laboratory testing. Appropriate management was initiated. However due to the advanced state of the patient’s disease, only slight improvement in spasticity was noted.
The information contained in this website is intended for healthcare providers and not for the general public.
Reference: 1. Bel S, et al. J Am Acad Dermatol. 2001;45:292-295.
©2024 Mirum Pharmaceuticals, Inc. All rights reserved. March 2024 US-DS-2300059